Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:
A happy couple looking at an iPad.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

BHP Group Ltd (ASX: BHP)

According to a note out of Goldman Sachs, its analysts have retained their buy rating on this mining giant's shares with a slightly reduced price target of $49.20. Goldman Sachs has been running the rule over the mining sector ahead of the release of quarterly updates this month. It believes BHP will deliver a reasonably solid quarterly update. For example, the broker expects copper and metallurgical coal production to increase quarter on quarter. But the main reasons the broker is positive are BHP's attractive valuation, its optionality with a +US$20 billion copper pipeline and strong production growth, and its robust free cash flow generation. The BHP share price was trading at $44.35 on Friday.

Mesoblast Ltd (ASX: MSB)

A note out of Bell Potter reveals that its analysts have retained their speculative buy rating on this cellular medicines developer's shares with an increased price target of $1.40. Bell Potter points out that the FDA has informed Mesoblast that available clinical data from a Phase 3 study for children with steroid refractory acute graft versus host disease appears sufficient to support a resubmission of the Biological Licence Application for its Remestemcel product. It believes the timing of the correspondence is no coincidence. The broker highlights that there is refreshed leadership at the newly formed Office of Therapeutic Products at the FDA. In light of this, its analysts have renewed confidence for a prospective approval of Remestemcel later this year. It also feels that a first approval may represent a gateway to a series of label expansions in the ensuing period. The Mesoblast share price was fetching 86.5 cents at the end of the week.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at UBS have retained their buy rating on this wine giant's shares with an improved price target of $15.25. This follows confirmation that the Chinese Ministry of Commerce (MOFCOM) is removing tariffs from Australian wine imports into China. According to the note, UBS was pleased with the news and believes that Treasury Wine's shares now deserve to trade on higher earnings multiples. Especially given that this news increases its addressable market. Its analysts have also lifted their earnings estimates to reflect the news and higher margin assumptions for its premium wine. The Treasury Wine share price ended the week at $12.86.

Motley Fool contributor James Mickleboro has positions in Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a graph indicating escalating results
Broker Notes

Why this buy-rated ASX energy share is tipped to more than double in 2026

A leading broker expects this rebounding ASX energy stock to rocket 104% in 2026. But why?

Read more »

Delighted adult man, working on a company slogan, on his laptop.
Broker Notes

Buy, hold, sell: CSL, Pinnacle, and Telix shares

Let's see what analysts are saying about these popular shares right now.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Top broker forecasts another 83% upside for this outperforming ASX All Ords tech stock

A leading broker expects outsized gains from this ASX All Ords tech stock in 2026. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Morgans names 2 ASX shares to buy now

The broker has good things to say about these shares.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

5 ASX 200 shares forecast to soar 100% (or more) in 2026

Are any of these in your portfolio already?

Read more »

A little boy in flying goggles and wings rides high on his mum's back with blue skies above.
Broker Notes

Bell Potter says this ASX 200 stock could rise 50%+

The broker thinks big returns could be on offer with this name.

Read more »

Woman with gold nuggets on her hand.
Broker Notes

Why this surging ASX 300 gold stock is forecast to keep on giving

A leading broker forecasts more outperformance from this rocketing ASX gold stock.

Read more »